Roche’s Raphael Pareschi on Pharmacovigilance, Regulatory Modernization and AI, Featured Interview by Xtalks
Toronto, ON (PRWEB) August 03, 2023 -- Pharmacovigilance is an essential and dynamic clinical discipline that holds tremendous importance in supporting public health. Pharmacovigilance activities ensure optimal use of drugs, early detection of safety signals and inform updates to product labeling or regulatory status.
In an article published today, Xtalks spoke with Raphael Elmadjian Pareschi, PharmD, MBA, Patient Safety Lead/Head of Pharmacovigilance Brazil at Roche to learn about how the pharmacovigilance space has evolved in recent years.
Dr. Pareschi shares his views on patient-centricity and AI, and makes some predictions regarding future challenges that will need to be addressed by pharmacovigilance professionals.
Dr. Pareschi is the chairperson for the upcoming Pharmacovigilance Peer Circle, an exclusive think-tank of high-level industry professionals looking for collaborative solutions to common challenges. Click here to learn more about how you can access this members-only event.
To read the full interview article featuring Dr. Raphael Pareschi, visit: Roche’s Raphael Pareschi on Pharmacovigilance, Regulatory Modernization and AI.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Sarah Hand, MSc., Xtalks, +1 (647) 621-4162, [email protected]
Share this article